Chiasma Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
24.39 M |
Public Float |
12.61 M |
Chiasma Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.35 |
Market Cap |
$187.51 M |
Shares Outstanding |
31.73 M |
Public Float |
13.56 M |
Address |
460 Totten Pond Road Waltham Massachusetts 02451 United States |
Employees | - |
Website | http://www.chiasmapharma.com |
Updated | 07/08/2019 |
Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The company's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. |